Question 1

What does peer-reviewed research say about these claims?

Accepted Answer

Bro translation: Mainstream medical consensus does not support the claim that 'natural interventions' can manage or cure systemic autoimmune diseases like Lupus or Hashimoto's, nor does it validate 'leaky gut' as a distinct, treatable disease entity. The literature also does not support the superiority of 'functional' hormone panels (Dutch) or gut tests (GI Map) over standard clinical diagnostics for diagnosing hormone imbalances or SIBO. The practice's claims of 'managing' autoimmunity and 'optimizing' hormones without standard medical oversight are unsupported and dangerous.

Question 2

Are Todd Anderson's credentials legitimate?

Accepted Answer

Dr. Todd Anderson and Dr. Anna Payne hold DC (Chiropractor) licenses but advertise diagnosing and treating systemic diseases (thyroid, hormones, autoimmunity, SIBO) that are strictly outside the scope of chiropractic practice. This is credential inflation: using a narrow musculoskeletal license to imply broad medical competence. Stated credentials: none detected. Likely credentials: Chiropractor (DC), DC. Credential inflation detected, a white coat is not the same as an MD/DO license.

Question 3

Is Dr Todd Anderson a real medical doctor?

Accepted Answer

Todd Anderson is not identified as an MD/DO physician in reviewed credentials or public registry data. Likely credential: Chiropractor (DC).

Question 4

Does Todd Anderson use False Authority?

Accepted Answer

The host uses the title 'Doctor' and 'Functional Medicine' to imply broad medical authority (endocrinology, immunology) that a chiropractic license (DC) does not grant. This is false authority. Likely motive: To attract patients with systemic diseases (thyroid, hormones, autoimmunity) who would otherwise see an MD/DO, thereby expanding the patient base beyond musculoskeletal issues.

Question 5

Does Todd Anderson use Lab Test Upsell?

Accepted Answer

The practice promotes 'functional' lab panels (Dutch, GI Map, organic acids) that are not standard of care, implying conventional labs are insufficient. This drives revenue from expensive, non-covered tests. Likely motive: To generate high-margin revenue from specialty lab tests (GI Map, Dutch) that insurance rarely covers, creating a cash-only revenue stream.

Question 6

Does Todd Anderson use Proprietary Product Funnel?

Accepted Answer

The host directs patients to a specific supplement dispensary (Fullscript) where they likely receive practitioner markup or referral fees, creating a proprietary product funnel. Likely motive: To earn direct financial compensation (markup/referral fees) from every supplement sold through their Fullscript link.

Question 7

Is the claim "Autoimmunity (Hashimoto's, psoriasis, lupus, and other autoimmune conditions managed by…" supported by medical literature?

Accepted Answer

Autoimmune diseases do cluster within individuals and families, and this pattern is consistent with shared genetic and environmental risk rather than a single universal trigger. Psoriasis has been associated with autoimmune thyroiditis and systemic lupus erythematosus in large observational datasets, which supports the idea that autoimmune conditions can co-occur and may share upstream biology. Hashimoto’s thyroiditis has also been associated with later systemic lupus erythematosus in cohort data, again supporting polyautoimmunity rather than isolated organ-specific disease. Major reviews of lupus and autoimmune disease describe environmental triggers and breakdown of immune tolerance as important contributors to disease development, and the lupus literature supports trigger avoidance for specific established triggers such as ultraviolet light and infection risk management. The claim is too broad and overstates what is proven. The index papers are hypothesis-generating or observational and do not show that autoimmune diseases are generally managed by identifying triggers, calming immune reactivity, and restoring tolerance naturally. Association studies cannot prove that identifying personal triggers will improve Hashimoto’s, psoriasis, lupus, or other autoimmune diseases, and they do not validate a natural-tolerance-restoration approach as an evidence-based treatment strategy. The more specific index items on common idiotypes and viral triggering are mechanistic or hypothesis papers, not clinical proof of effective management. Mainstream guidelines for lupus emphasize evidence-based medical therapy, monitoring, and targeted lifestyle measures, not a general claim that autoimmunity is managed naturally by restoring tolerance. Evidence for broad trigger elimination, immune calming protocols, or “restoring tolerance” as a general clinical method remains weak, heterogeneous, and not established across autoimmune diseases. Mainstream medicine recognizes that autoimmune diseases are multifactorial, with genetic susceptibility, environmental factors, and immune dysregulation contributing to onset and flares. Clinicians do identify and avoid specific, disease-relevant triggers when they are well established, such as ultraviolet exposure in lupus, infections, certain medications, smoking, and other individualized exacerbating factors, but this is adjunctive care rather than a universal or curative strategy. The standard of care is diagnosis-specific evidence-based treatment; the idea that Hashimoto’s, psoriasis, lupus, and other autoimmune conditions are generally managed by naturally restoring immune tolerance is not accepted as a proven broad clinical framework. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim). Literature verdict: mixed.

Question 8

Is the claim "Thyroid Support (Hypothyroid, Hashimoto's, and subclinical thyroid dysfunction — includ…" supported by medical literature?

Accepted Answer

High-quality guidelines and reviews recognize subclinical thyroid dysfunction (including subclinical hypothyroidism and hyperthyroidism) as a laboratory diagnosis based on abnormal TSH with normal free T4, and they emphasize that TSH plus FT4 testing is required to identify these conditions. This means that relying on TSH alone can miss some subclinical thyroid dysfunction, and adding FT4 (and in some contexts FT3) is considered standard in more detailed evaluation. Major reviews and guidelines further note that subclinical thyroid dysfunction is associated with cardiovascular risk, heart failure, and mortality, which justifies careful screening and follow-up in at‑risk patients. Endothelial dysfunction and adverse cardiovascular parameters have been demonstrated in patients with subclinical thyroid dysfunction, supporting the clinical relevance of detecting these states even when routine tests appear “normal.” There is consensus that thyroid antibody testing (especially thyroid peroxidase antibodies) helps identify autoimmune thyroiditis such as Hashimoto’s and stratify risk of progression from subclinical to overt hypothyroidism, which can be missed if only TSH is checked. This supports the idea that more complete thyroid panels (TSH, FT4, sometimes FT3, and antibodies) are clinically useful beyond minimal conventional screening, particularly in suspected autoimmune disease or borderline results. The claim that conventional labs “miss entirely” comprehensive thyroid panels is not supported; major guidelines and reviews describe standard diagnostic panels that routinely include TSH and free T4, with antibody testing when autoimmune thyroid disease is suspected, and do not consider these tests exotic or non‑conventional. Subclinical thyroid dysfunction is already defined and managed based on conventional laboratory testing (TSH with FT4), so it is inaccurate to suggest that mainstream medicine fails to recognize or test for these conditions. High‑quality evidence and major guidelines emphasize individualized treatment and often a watchful waiting approach for subclinical hypothyroidism, reflecting uncertainty about benefit from routine intervention; they do not support aggressive or universal “thyroid support” for all patients with subclinical abnormalities. For many patients with mild TSH elevation and normal FT4, especially older adults, guidelines advise monitoring rather than routine pharmacologic treatment, indicating that simply finding subclinical dysfunction on more expansive panels does not automatically warrant therapy. No high‑quality evidence supports the notion that large, influencer‑style “comprehensive panels” (far beyond TSH, FT4, FT3, and antibodies) are necessary for most patients or that they detect clinically important thyroid problems that conventional guideline‑based testing systematically misses. Mainstream endocrinology defines hypothyroidism and Hashimoto’s disease using standard thyroid function tests (TSH, free T4) plus thyroid autoantibodies when indicated, and recognizes subclinical thyroid dysfunction as a biochemical abnormality diagnosed with these same conventional assays. Current major guidelines support using TSH as the first‑line screening test, with reflex measurement of FT4 (and, in selected cases, FT3) to characterize subclinical or overt dysfunction and to guide further management. Thyroid antibody testing is recommended when autoimmune thyroid disease is suspected or when risk stratification for progression from subclinical to overt hypothyroidism is needed, not as a universal panel for everyone. Management of subclinical hypothyroidism and hyperthyroidism is individualized; treatment is clearly supported when TSH is markedly abnormal or when there are specific risk factors (e.g., cardiovascular disease, pregnancy), but routine treatment of all subclinical cases is not recommended because evidence for benefit is limited and mixed. The mainstream position is that conventional lab testing, applied according to guidelines, is generally sufficient to detect clinically relevant hypothyroidism, Hashimoto’s, and subclinical thyroid dysfunction, and that very broad, non‑standard “comprehensive thyroid panels” marketed by influencers go beyond what evidence and guidelines support for most patients. Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim). Literature verdict: mixed.

Todd Anderson alias The Biomarker Baron

Score breakdown

Key findings

Claims & evidence

Manipulation

Borrowed authority & guest funnel

Host self-funnel

Commerce & grift map

Fullscript

Rupa Health

Dutch Health (Dutch Hormone Panel)

BiomeFX (GI Map)

Supplements pitched

Labs pitched

How the money flows

Store links detected

Sponsors and advertisers

Credentials & scope

Minnesota Board of Chiropractic Examiners

Disclaimer hypocrisy

When the service is also outside their license

Validated associated properties

Analyzed

Funnel routes (third-party)

Tip the jar

Fight disinformation

Log a new mention

Reply snippets

Recent mentions (this doc)

Nudge the Doc Bro

Pick a contact address

What gets sent

Know someone who can help?

Who should we nudge?

What gets sent

Whambulance

Public challenge log

File a challenge

Citations